1442472-39-0

Ripretinib is used in the treatment of gastrointestinal stromal tumors (GISTs).

Qinlock

Class: receptor tyrosine kinase; Treatment: GIST; Other name: DCC-2618; Elimination half-life = 15 h; Protein binding = 98.8%

Ripretinib is a highly effective inhibitor of both wild-type KIT and PDGFRA, with IC50 values around 3 nM. It also targets a wide range of KIT and PDGFRA mutants in GIST. Additionally, it inhibits various tumor-driving kinases such as PDGFRβ, TIE2, VEGFR2, and BRAF.

Primary targets: PDGFRA, KIT